Table 4.
RF (n=502) | Cryoballoon (n=190) | P Value | |
---|---|---|---|
Overweight patients (BMI >30 kg/m2) | |||
All complications | 4.6% (23) | 7.9% (15) | 0.090 |
Cardiac tamponade | 1.0% (5) | 0.5% (1) | 0.552 |
Stroke | 0.2% (1) | 0.5% (1) | 0.474 |
Phrenic nerve palsy | 0.4% (2) | 4.2% (8) | <0.001 |
Vascular complications | 1.6% (8) | 2.6% (5) | 0.369 |
Other bleeds | 0.2% (1) | 0% (0) | 0.538 |
Bradyarrhythmic complications | 0.2% (1) | 0% (0) | 0.538 |
Gastroparesis | 0.2% (1) | 0% (0) | 0.538 |
Transient myocardial stunning | 0.2% (1) | 0% (0) | 0.538 |
Acute pulmonary edema | 0.2% (1) | 0% (0) | 0.538 |
NOAC (n=180) | VKA (n=512) | P Value | |
---|---|---|---|
Overweight patients (BMI >30 kg/m2) | |||
Stroke | 0% (0) | 0.4% (2) | 0.401 |
TIA | 0% (0) | 0% (0) | N.A. |
Systemic embolism | 0% (0) | 0% (0) | N.A. |
Cardiac tamponade | 0.6% (1) | 1.0% (5) | 0.600 |
Vascular complications | 1.7% (3) | 2.0% (10) | 0.808 |
Other bleeds | 0% (0) | 0.2% (1) | 0.538 |
NOAC (n=61) | VKA (n=123) | P Value | |
---|---|---|---|
Patients with BMI >35 kg/m2 | |||
Stroke | 0% (0) | 0% (0) | N.A. |
TIA | 0% (0) | 0% (0) | N.A. |
Systemic embolism | 0% (0) | 0% (0) | N.A. |
Cardiac tamponade | 0% (0) | 1.6% (2) | 0.317 |
Vascular complications | 1.6% (1) | 0% (0) | 0.154 |
Other bleeds | 0% (0) | 0% (0) | N.A. |
NOAC (n=13) | VKA (n=26) | P Value | |
---|---|---|---|
Patients with BMI >40 kg/m2 | |||
Stroke | 0% (0) | 0% (0) | N.A. |
TIA | 0% (0) | 0% (0) | N.A. |
Systemic embolism | 0% (0) | 0% (0) | N.A. |
Cardiac tamponade | 0% (0) | 3.8% (1) | 0.474 |
Vascular complications | 0% (0) | 0% (0) | N.A. |
Other bleeds | 0% (0) | 0% (0) | N.A. |
NOAC (n=23) | VKA (n=36) | P Value | |
---|---|---|---|
Patients weighting >120 kg | |||
Stroke | 0% (0) | 0% (0) | N.A. |
TIA | 0% (0) | 0% (0) | N.A. |
Systemic embolism | 0% (0) | 0% (0) | N.A. |
Cardiac tamponade | 0% (0) | 0% (0) | N.A. |
Vascular complications | 0% (0) | 0% (0) | N.A. |
Other bleeds | 0% (0) | 0% (0) | N.A. |
BMI indicates body mass index; NOAC, novel oral anticoagulants; RF, radio frequency; TIA, transient ischemic attack; VKA, vitamin K antagonists.